ChemoCentryx Inc.

50.60-0.2700-0.53%Vol 6.33M1Y Perf 253.02%
Aug 11th, 2022 16:00 DELAYED
BID50.70 ASK50.90
Open50.85 Previous Close50.87
Pre-Market- After-Market50.66
 - -  0.06 0.12%
Target Price
73.83 
Analyst Rating
Hold 2.71
Potential %
45.91 
Finscreener Ranking
+     36.88
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★     45.55
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
     36.62
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
99.10 
Earnings Rating
Neutral
Market Cap3.61B 
Earnings Date
9th Aug 2022
Alpha0.05 Standard Deviation0.40
Beta1.81 

Today's Price Range

50.5951.06

52W Range

13.1150.94

5 Year PE Ratio Range

-31.3040.80

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.16%
1 Month
123.50%
3 Months
191.64%
6 Months
69.80%
1 Year
253.02%
3 Years
649.63%
5 Years
602.78%
10 Years
359.17%

TickerPriceChg.Chg.%
CCXI50.60-0.2700-0.53
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
98.10
-508.70
-493.80
-415.90
-92.18
RevenueValueIndustryS&P 500US Markets
25.44M
0.36
-5.99
-0.59
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.51-0.4413.73
Q01 2022-0.30-0.55-83.33
Q04 2021-0.57-0.58-1.75
Q03 2021-0.46-0.3230.43
Q02 2021-0.55-0.56-1.82
Q01 2021-0.40-0.43-7.50
Q04 2020-0.32-0.43-34.38
Q03 2020-0.28-0.35-25.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.505.66Positive
9/2022 QR-0.466.12Positive
12/2022 FY-1.93-11.56Negative
12/2023 FY-0.98-71.93Negative
Next Report Date-
Estimated EPS Next Report-0.51
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume6.33M
Shares Outstanding71.36K
Shares Float57.45M
Trades Count37.42K
Dollar Volume321.34M
Avg. Volume5.86M
Avg. Weekly Volume12.26M
Avg. Monthly Volume3.31M
Avg. Quarterly Volume2.00M

ChemoCentryx Inc. (NASDAQ: CCXI) stock closed at 50.6 per share at the end of the most recent trading day (a -0.53% change compared to the prior day closing price) with a volume of 6.33M shares and market capitalization of 3.61B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 82 people. ChemoCentryx Inc. CEO is Thomas J. Schall.

The one-year performance of ChemoCentryx Inc. stock is 253.02%, while year-to-date (YTD) performance is 38.97%. CCXI stock has a five-year performance of 602.78%. Its 52-week range is between 13.11 and 50.94, which gives CCXI stock a 52-week price range ratio of 99.10%

ChemoCentryx Inc. currently has a PE ratio of -11.40, a price-to-book (PB) ratio of 6.31, a price-to-sale (PS) ratio of 62.55, a price to cashflow ratio of 40.20, a PEG ratio of 2.32, a ROA of -30.85%, a ROC of -36.42% and a ROE of -46.91%. The company’s profit margin is -92.18%, its EBITDA margin is -493.80%, and its revenue ttm is $25.44 Million , which makes it $0.36 revenue per share.

Of the last four earnings reports from ChemoCentryx Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.51 for the next earnings report. ChemoCentryx Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for ChemoCentryx Inc. is Hold (2.71), with a target price of $73.83, which is +45.91% compared to the current price. The earnings rating for ChemoCentryx Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ChemoCentryx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ChemoCentryx Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.84, ATR14 : 2.47, CCI20 : 111.54, Chaikin Money Flow : 0.00, MACD : 7.11, Money Flow Index : 88.98, ROC : 120.77, RSI : 79.54, STOCH (14,3) : 98.42, STOCH RSI : 0.98, UO : 86.76, Williams %R : -1.58), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ChemoCentryx Inc. in the last 12-months were: Geoffrey M. Parker (Option Excercise at a value of $180 250), Henry A. McKinnell (Option Excercise at a value of $0), James L. Tyree (Option Excercise at a value of $0), James L. Tyree (Sold 13 863 shares of value $601 329 ), Joseph M. Feczko (Option Excercise at a value of $577 750), Markus J. Cappel (Option Excercise at a value of $0), Markus J. Cappel (Sold 7 564 shares of value $379 864 ), Rita I. Jain (Option Excercise at a value of $0), Susan M. Kanaya (Option Excercise at a value of $300 805), Susan M. Kanaya (Sold 46 298 shares of value $2 322 715 ), Thomas J. Schall (Option Excercise at a value of $1 856 400), Thomas J. Schall (Sold 130 000 shares of value $6 531 733 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (14.29 %)
5 (83.33 %)
5 (83.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
6 (85.71 %)
1 (16.67 %)
1 (16.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
2.71
Strong Buy
1.33
Strong Buy
1.33

ChemoCentryx Inc.

ChemoCentryx Inc is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

CEO: Thomas J. Schall

Telephone: +1 650 210-2900

Address: 850 Maude Avenue, Mountain View 94043, CA, US

Number of employees: 82

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

50%50%

Bearish Bullish

48%52%

Bearish Bullish

56%44%

TipRanks News for CCXI

Tue, 09 Aug 2022 13:40 GMT Analysts Offer Insights on Healthcare Companies: ChemoCentryx (CCXI) and ATI Physical Therapy (ATIP)

- TipRanks. All rights reserved.

Thu, 30 Jun 2022 04:55 GMT Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), ChemoCentryx (CCXI) and Jazz Pharmaceuticals (JAZZ)

- TipRanks. All rights reserved.

Wed, 01 Jun 2022 10:15 GMT Analysts Top Healthcare Picks: ChemoCentryx (CCXI), MannKind (MNKD)

- TipRanks. All rights reserved.

Sun, 22 May 2022 08:46 GMT Can ChemoCentryx Control Challenging Capital Complications

- TipRanks. All rights reserved.

Sun, 08 May 2022 15:19 GMT ChemoCentryx (CCXI) Gets a Buy Rating from SVB Securities

- TipRanks. All rights reserved.

Fri, 15 Apr 2022 03:05 GMT Analysts Offer Insights on Healthcare Companies: ChemoCentryx (CCXI), Tenet Healthcare (THC) and Turning Point Therapeutics (TPTX)

- TipRanks. All rights reserved.

Wed, 02 Mar 2022 11:25 GMT Analysts Are Bullish on These Healthcare Stocks: ChemoCentryx (CCXI), Taro Pharmaceutical (TARO)

- TipRanks. All rights reserved.

Tue, 15 Feb 2022 16:15 GMT ChemoCentryx (CCXI) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

Wed, 19 Jan 2022 14:35 GMT ChemoCentryx (CCXI) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Tue, 18 Jan 2022 15:45 GMT ChemoCentryx (CCXI) Gets a Buy Rating from Leerink Partners

- TipRanks. All rights reserved.

News

Stocktwits